



Situation of biosimilar candidates whose originator medicine is estimated to lose market exclusivity before 2030



At each stage, the total number of biosimilar candidates is indicated
*Active ingredient for which there is already a biosimilar on the market

Number of clinical trials of biosimilars included in the horizon scanning carried out in Spain



Medical centers with active clinical trials

Active ingredient	Medical centers
Aflibercept	<ul style="list-style-type: none"> > Centre D'oftalmologia Barraquer (Barcelona) > Hospital Universitario Río Hortega (Valladolid)
Denosumab	<ul style="list-style-type: none"> > Gaias Research (Coruña) > Hospital de Sabadell (Barcelona) > Hospital HM Esperanza (Coruña) > Instituto Palacios Salud y Medicina de La Mujer (Madrid) > Complejo Hospitalario Universitario de Santiago (Coruña) > Hospital de la Santa Creu i Sant Pau (Barcelona) > Hospital Quironsalud Infanta Luisa (Sevilla) > Hospital Universitario y Politécnico La Fe (Valencia) > Complejo Hospitalario Universitario A Coruña (Coruña) > Hospital Universitario Regional de Málaga (Málaga)
Nivolumab	<ul style="list-style-type: none"> > Hospital Jerez Puerta del Sur Grupo Hla S.A. (Cádiz) > Hospital Universitari Vall D'Hebron (Barcelona) > Hospital Universitario Virgen de la Macarena (Sevilla) > Hospital General Universitario de Valencia (Valencia) > Hospital San Pedro de Alcántara (Cáceres) > Hospital Universitario Regional de Málaga (Málaga) > Hospital Clínico Universitario Virgen de la Arrixaca (Murcia)
Pertuzumab	<ul style="list-style-type: none"> > Hospital Universitari Arnau de Vilanova de Lleida (Lérida)
Ustekinumab	<ul style="list-style-type: none"> > Hospital Manises (Valencia) > Hospital Universitario 12 de Octubre (Madrid)